Jessica Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jessica Chang has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
- Phillip F. Halloran
Alberta Transplant Applied Genomics Centre, Edmonton, University of Alberta, Canada
18 shared publications B. Sis
Department of Laboratory Medicine and Pathology, Division of Nephrology and Transplant Immunology, University of Alberta, Edmonton, Alberta, Canada
7 shared publicationsM. Mengel
Department of Laboratory Medicine and Pathology, Division of Nephrology and Transplant Immunology, University of Alberta, Edmonton, Alberta, Canada
7 shared publicationsG. Einecke
Department of Nephrology, Hannover Medical School, Hannover, Germany
6 shared publicationsL. G. Hidalgo
Department of Laboratory Medicine and Pathology, Division of Nephrology and Transplant Immunology, University of Alberta, Edmonton, Alberta, Canada
6 shared publicationsD. G. de Freitas
Alberta Transplant Applied Genomic Centre, Manchester, UK
4 shared publications
Latest Publications
- 23 May 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (10) , 1711-1712
Response to “Letter to the editor” from Dr. Paul Corris
- 23 May 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (10) , 1711-1712
Response to “Letter to the editor” from Dr. Paul Corris
- Open Access
- 5 May 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (12)
Impact of older donor age in kidney transplants in a biopsy-based observational study
Because older donor age is a major concern when considering kidneys for potential transplantation, we explored the actual effect of donor age on the features of kidneys that have been transplanted. We studied the correlations of donor age with molecular injury and rejection scores in 4,502 kidney transplant biopsies assessed by microarrays as well as function and postbiopsy survival. We used multivariable analyses to correct for the correlations of donor age with other predictive variables: recipient age, time of biopsy after transplant, and deceased versus living donors. Older donor age correlated with lower glomerular filtration rate (GFR) and increased acute and chronic injury transcripts but had no effect on rejection, which was anticorrelated with recipient age. Acute injury transcripts peaked immediately after transplant and regressed. Older donor age had little effect on acute molecular injury immediately after transplant but strongly increased molecular injury scores at later times, peaking about 1-year after transplant, indicating that older age does not increase molecular injury but increases failed repair after injury. As expected, older donor age correlated with increased chronic injury and lower GFR, evident from the earliest time after transplant, pretransplant aging. However, despite substantial age-related effects, the quantitative contribution of donor aging to molecular injury, function, and survival was very small.
- 5 May 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (12)
Open AccessImpact of older donor age in kidney transplants in a biopsy-based observational study
Because older donor age is a major concern when considering kidneys for potential transplantation, we explored the actual effect of donor age on the features of kidneys that have been transplanted. We studied the correlations of donor age with molecular injury and rejection scores in 4,502 kidney transplant biopsies assessed by microarrays as well as function and postbiopsy survival. We used multivariable analyses to correct for the correlations of donor age with other predictive variables: recipient age, time of biopsy after transplant, and deceased versus living donors. Older donor age correlated with lower glomerular filtration rate (GFR) and increased acute and chronic injury transcripts but had no effect on rejection, which was anticorrelated with recipient age. Acute injury transcripts peaked immediately after transplant and regressed. Older donor age had little effect on acute molecular injury immediately after transplant but strongly increased molecular injury scores at later times, peaking about 1-year after transplant, indicating that older age does not increase molecular injury but increases failed repair after injury. As expected, older donor age correlated with increased chronic injury and lower GFR, evident from the earliest time after transplant, pretransplant aging. However, despite substantial age-related effects, the quantitative contribution of donor aging to molecular injury, function, and survival was very small.
- 19 November 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (3) , 403-414
Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort
- 19 November 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (3) , 403-414
Molecular biopsy features associated with baseline lung allograft dysfunction in a multicenter international cohort
- Top Cited PapersOpen Access
- 29 April 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (5) , 1668-1676
Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies
A recent randomized controlled trial demonstrated that treatment with anti-CD38 monoclonal antibody felzartamab suppressed antibody-mediated rejection (ABMR) in kidney transplant patients but with recurrence after treatment in some patients. Here we examined the molecular effects of 6 months of felzartamab treatment on biopsies from the trial using genome-wide microarray analysis, comparing pretreatment, end-of-treatment (week 24) and posttreatment (week 52) biopsies from ten patients treated with felzartamab and ten patients in the placebo group. Felzartamab reduced molecular ABMR activity scores in all nine patients with baseline ABMR activity, selectively suppressing interferon gamma-inducible and natural killer cell transcripts, with minimal effect on ABMR stage-related endothelial transcripts. Suppression was often incomplete when ABMR activity was intense, and molecular recurrence was nearly universal by week 52. However, we also found that felzartamab had parenchymal benefits at week 52, slowing the trajectories of molecular injury scores beyond the treatment period, suggesting that suppression of ABMR activity could potentially slow future progression to kidney failure. These data provide preliminary molecular insights into the effects of CD38-directed treatment for ABMR, which have the potential to inform future therapeutic strategies.
- 29 April 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (5) , 1668-1676
Top Cited PapersOpen AccessEffect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies
A recent randomized controlled trial demonstrated that treatment with anti-CD38 monoclonal antibody felzartamab suppressed antibody-mediated rejection (ABMR) in kidney transplant patients but with recurrence after treatment in some patients. Here we examined the molecular effects of 6 months of felzartamab treatment on biopsies from the trial using genome-wide microarray analysis, comparing pretreatment, end-of-treatment (week 24) and posttreatment (week 52) biopsies from ten patients treated with felzartamab and ten patients in the placebo group. Felzartamab reduced molecular ABMR activity scores in all nine patients with baseline ABMR activity, selectively suppressing interferon gamma-inducible and natural killer cell transcripts, with minimal effect on ABMR stage-related endothelial transcripts. Suppression was often incomplete when ABMR activity was intense, and molecular recurrence was nearly universal by week 52. However, we also found that felzartamab had parenchymal benefits at week 52, slowing the trajectories of molecular injury scores beyond the treatment period, suggesting that suppression of ABMR activity could potentially slow future progression to kidney failure. These data provide preliminary molecular insights into the effects of CD38-directed treatment for ABMR, which have the potential to inform future therapeutic strategies.
- Open Access
- 15 April 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (10)
A cross-sectional study of the role of epithelial cell injury in kidney transplant outcomes
Background. Expression of acute kidney injury–associated (AKI-associated) transcripts in kidney transplants may reflect recent injury and accumulation of epithelial cells in “failed repair” states. We hypothesized that the phenomenon of failed repair could be associated with deterioration and failure in kidney transplants. Methods. We defined injury-induced transcriptome states in 4,502 kidney transplant biopsies injury-induced gene sets and classifiers previously developed in transplants. Results. In principal component analysis (PCA), PC1 correlated with both acute and chronic kidney injury and related inflammation and PC2 with time posttransplant. Positive PC3 was a dimension that correlated with epithelial remodeling pathways and anticorrelated with inflammation. Both PC1 and PC3 correlated with reduced survival, with PC1 effects strongly increasing over time whereas PC3 effects were independent of time. In this model, we studied the expression of 12 “new” gene sets annotated in single-nucleus RNA-sequencing studies of epithelial cells with failed repair in native kidneys. The new gene sets reflecting epithelial-mesenchymal transition correlated with injury PC1 and PC3, lower estimated glomerular filtration rate, higher donor age, and future failure as strongly as any gene sets previously derived in transplants and were independent of nephron segment of origin and graft rejection. Conclusion. These results suggest 2 dimensions in the kidney transplant response to injury: PC1, AKI-induced changes, failed repair, and inflammation; and PC3, a response involving epithelial remodeling without inflammation. Increasing kidney age amplifies PC1 and PC3. Trial registration. INTERCOMEX (ClinicalTrials.gov NCT01299168); Trifecta-Kidney (ClinicalTrials.gov NCT04239703). Funding. Genome Canada; Natera, Inc.; and Thermo Fisher Scientific.
- 15 April 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (10)
Open AccessA cross-sectional study of the role of epithelial cell injury in kidney transplant outcomes
Background. Expression of acute kidney injury–associated (AKI-associated) transcripts in kidney transplants may reflect recent injury and accumulation of epithelial cells in “failed repair” states. We hypothesized that the phenomenon of failed repair could be associated with deterioration and failure in kidney transplants. Methods. We defined injury-induced transcriptome states in 4,502 kidney transplant biopsies injury-induced gene sets and classifiers previously developed in transplants. Results. In principal component analysis (PCA), PC1 correlated with both acute and chronic kidney injury and related inflammation and PC2 with time posttransplant. Positive PC3 was a dimension that correlated with epithelial remodeling pathways and anticorrelated with inflammation. Both PC1 and PC3 correlated with reduced survival, with PC1 effects strongly increasing over time whereas PC3 effects were independent of time. In this model, we studied the expression of 12 “new” gene sets annotated in single-nucleus RNA-sequencing studies of epithelial cells with failed repair in native kidneys. The new gene sets reflecting epithelial-mesenchymal transition correlated with injury PC1 and PC3, lower estimated glomerular filtration rate, higher donor age, and future failure as strongly as any gene sets previously derived in transplants and were independent of nephron segment of origin and graft rejection. Conclusion. These results suggest 2 dimensions in the kidney transplant response to injury: PC1, AKI-induced changes, failed repair, and inflammation; and PC3, a response involving epithelial remodeling without inflammation. Increasing kidney age amplifies PC1 and PC3. Trial registration. INTERCOMEX (ClinicalTrials.gov NCT01299168); Trifecta-Kidney (ClinicalTrials.gov NCT04239703). Funding. Genome Canada; Natera, Inc.; and Thermo Fisher Scientific.
- Open Access
- 7 August 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (1) , 72-87
Subthreshold rejection activity in many kidney transplants currently classified as having no rejection
- 7 August 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (1) , 72-87
Open AccessSubthreshold rejection activity in many kidney transplants currently classified as having no rejection
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S374-S375
Sa1827 Molecular Landscape of Ulcerative Colitis and Crohn's Disease is Conserved
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S374-S375
Sa1827 Molecular Landscape of Ulcerative Colitis and Crohn's Disease is Conserved
- Open Access
- 28 January 2013
- Published by Elsevier in American Journal of Transplantation
- Vol. 13 (3) , 634-644
Kidney Transplants With Progressing Chronic Diseases Express High Levels of Acute Kidney Injury Transcripts
- 28 January 2013
- Published by Elsevier in American Journal of Transplantation
- Vol. 13 (3) , 634-644
Open AccessKidney Transplants With Progressing Chronic Diseases Express High Levels of Acute Kidney Injury Transcripts
- Open Access
- 2 January 2013
- Published by Elsevier in American Journal of Transplantation
- Vol. 13 (2) , 415-426
Comparing Molecular Assessment of Implantation Biopsies With Histologic and Demographic Risk Assessment
- 2 January 2013
- Published by Elsevier in American Journal of Transplantation
- Vol. 13 (2) , 415-426
Open AccessComparing Molecular Assessment of Implantation Biopsies With Histologic and Demographic Risk Assessment
- 1 May 2012
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 23 (5) , 948-958
Molecular Phenotypes of Acute Kidney Injury in Kidney Transplants
Little is known regarding the molecular phenotype of kidneys with AKI because biopsies are performed infrequently. However, all kidney transplants experience acute injury, making early kidney transplants an excellent model of acute injury, provided the absence of rejection, because donor kidneys should not have CKD, post-transplant biopsies occur relatively frequently, and follow-up is excellent typically. Here, we used histopathology and microarrays to compare indication biopsies from 26 transplants with acute injury with 11 pristine protocol biopsies of stable transplants. Kidneys with acute injury showed increased expression of 394 transcripts associated with the repair response to injury, including many epithelium-like injury molecules tissue, remodeling molecules, and inflammation molecules. Many other genes also predicted the phenotype, including the acute injury biomarkers HAVCR1 and IL18. Pathway analysis of the injury-repair transcripts revealed similarities to cancer, development, and cell movement. The injury-repair transcript score in kidneys with acute injury correlated with reduced graft function, future renal recovery, brain death, and need for dialysis, but not with future graft loss. In contrast, histologic features of acute tubular injury did not correlate with function or with the molecular changes. Thus, the transcripts associated with repair of injury suggest a massive coordinated response of the kidney parenchyma to acute injury, providing both an objective measure for assessing the severity of injury in kidney biopsies and validation for many biomarkers of AKI.
- 1 May 2012
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 23 (5) , 948-958
Molecular Phenotypes of Acute Kidney Injury in Kidney Transplants
Little is known regarding the molecular phenotype of kidneys with AKI because biopsies are performed infrequently. However, all kidney transplants experience acute injury, making early kidney transplants an excellent model of acute injury, provided the absence of rejection, because donor kidneys should not have CKD, post-transplant biopsies occur relatively frequently, and follow-up is excellent typically. Here, we used histopathology and microarrays to compare indication biopsies from 26 transplants with acute injury with 11 pristine protocol biopsies of stable transplants. Kidneys with acute injury showed increased expression of 394 transcripts associated with the repair response to injury, including many epithelium-like injury molecules tissue, remodeling molecules, and inflammation molecules. Many other genes also predicted the phenotype, including the acute injury biomarkers HAVCR1 and IL18. Pathway analysis of the injury-repair transcripts revealed similarities to cancer, development, and cell movement. The injury-repair transcript score in kidneys with acute injury correlated with reduced graft function, future renal recovery, brain death, and need for dialysis, but not with future graft loss. In contrast, histologic features of acute tubular injury did not correlate with function or with the molecular changes. Thus, the transcripts associated with repair of injury suggest a massive coordinated response of the kidney parenchyma to acute injury, providing both an objective measure for assessing the severity of injury in kidney biopsies and validation for many biomarkers of AKI.